Exelixis, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved CABOMETYX® (cabozantinib) for the treatment of 1) adult and pediatric patients 12 years of age and older ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback